Inozyme Pharma, Inc. – NASDAQ:INZY
Founder-led company
Inozyme Pharma stock price today
$3.99
+1.07
+36.64%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Inozyme Pharma stock price monthly change
-43.30%
month
Inozyme Pharma stock price quarterly change
-43.30%
quarter
Inozyme Pharma stock price yearly change
-35.11%
year
Inozyme Pharma key metrics
Market Cap | 182.12M |
Enterprise value | 196.28M |
P/E | -2.87 |
EV/Sales | N/A |
EV/EBITDA | -2.95 |
Price/Sales | N/A |
Price/Book | 1.87 |
PEG ratio | -0.11 |
EPS | -1.37 |
Revenue | N/A |
EBITDA | -81.10M |
Income | -77.11M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInozyme Pharma stock price history
Inozyme Pharma stock forecast
Inozyme Pharma financial statements
| Jun 2023 | 0 | -15.58M | |
|---|---|---|---|
| Sep 2023 | 0 | -16.63M | |
| Dec 2023 | 1.97M | -21.54M | -1090.28% |
| Mar 2024 | 0 | -23.34M |
| Mar 2024 | 0 | -23.34M | |
|---|---|---|---|
| Sep 2025 | 0 | -26.16M | |
| Oct 2025 | 0 | -25.94M | |
| Dec 2025 | 0 | -26.25M |
Analysts Price target
Financials & Ratios estimates
| 2023-11-07 | -0.32 | -0.29 |
|---|---|---|
| 2024-03-12 | -0.31 | -0.35 |
| Jun 2023 | 150929000 | 45.33M | 30.04% |
|---|---|---|---|
| Sep 2023 | 205702000 | 45.48M | 22.11% |
| Dec 2023 | 200847000 | 60.36M | 30.06% |
| Mar 2024 | 176943000 | 58.10M | 32.84% |
| Jun 2023 | -15.54M | -16.32M | 23.64M |
|---|---|---|---|
| Sep 2023 | -18.86M | -44.61M | 69.71M |
| Dec 2023 | -18.48M | -6.47M | 12.51M |
| Mar 2024 | -24.53M | 10.39M | 159K |
Inozyme Pharma alternative data
| Aug 2023 | 56 |
|---|---|
| Sep 2023 | 56 |
| Oct 2023 | 56 |
| Nov 2023 | 56 |
| Dec 2023 | 56 |
| Jan 2024 | 56 |
| Feb 2024 | 56 |
| Mar 2024 | 59 |
| Apr 2024 | 59 |
| May 2024 | 59 |
| Jun 2024 | 59 |
| Jul 2024 | 59 |
Inozyme Pharma other data
27.94%
-38.67%
of INZY is owned by hedge funds
22
-14
10.55M
-18.53M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 447932 | 0 |
| Aug 2023 | 1666666 | 0 |
| Apr 2024 | 0 | 7523 |
| Patent |
|---|
Application Filling date: 25 Nov 2020 Issue date: 30 Sep 2021 |
Application Filling date: 17 Feb 2021 Issue date: 24 Jun 2021 |
| Insider | Compensation |
|---|---|
Mr. Axel Bolte M.B.A., M.Sc. (1972) Co-Founder, Pres, Chief Executive Officer & Director | $771,400 |
| Mr. Henric Bjorn Bjarke (1967) Senior Vice President & Chief Operating Officer | $576,880 |
-
What's the price of Inozyme Pharma stock today?
One share of Inozyme Pharma stock can currently be purchased for approximately $3.99.
-
When is Inozyme Pharma's next earnings date?
Unfortunately, Inozyme Pharma's (INZY) next earnings date is currently unknown.
-
Does Inozyme Pharma pay dividends?
No, Inozyme Pharma does not pay dividends.
-
How much money does Inozyme Pharma make?
Inozyme Pharma has a market capitalization of 182.12M. Inozyme Pharma made a loss 71.17M US dollars in net income (profit) last year or -$0.35 on an earnings per share basis.
-
What is Inozyme Pharma's stock symbol?
Inozyme Pharma, Inc. is traded on the NASDAQ under the ticker symbol "INZY".
-
What is Inozyme Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Inozyme Pharma?
Shares of Inozyme Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Inozyme Pharma's key executives?
Inozyme Pharma's management team includes the following people:
- Mr. Axel Bolte M.B.A., M.Sc. Co-Founder, Pres, Chief Executive Officer & Director(age: 53, pay: $771,400)
- Mr. Henric Bjorn Bjarke Senior Vice President & Chief Operating Officer(age: 58, pay: $576,880)
-
Is Inozyme Pharma founder-led company?
Yes, Inozyme Pharma is a company led by its founder Mr. Axel Bolte M.B.A., M.Sc..
-
How many employees does Inozyme Pharma have?
As Jul 2024, Inozyme Pharma employs 59 workers.
-
When Inozyme Pharma went public?
Inozyme Pharma, Inc. is publicly traded company for more then 5 years since IPO on 24 Jul 2020.
-
What is Inozyme Pharma's official website?
The official website for Inozyme Pharma is inozyme.com.
-
Where are Inozyme Pharma's headquarters?
Inozyme Pharma is headquartered at 321 Summer Street, Boston, MA.
-
How can i contact Inozyme Pharma?
Inozyme Pharma's mailing address is 321 Summer Street, Boston, MA and company can be reached via phone at 857 330 4340.
Inozyme Pharma company profile:
Inozyme Pharma, Inc.
inozyme.comExchange:
NASDAQ
Full time employees:
59
Industry:
Biotechnology
Sector:
Healthcare
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
321 Summer Street
Boston, MA 02210
Boston, MA 02210
CIK: 0001693011
ISIN: US45790W1080
CUSIP: 45790W108
